BUSINESS
FTC Hits Torii with Cease, Desist, and Surcharge Payment Order over Price-Fixing for Calvan
Japan’s Fair Trade Commission (FTC) on March 5 issued a cease and desist order and a surcharge payment order to Torii Pharmaceutical for violating the Antimonopoly Act by price-fixing with Nippon Chemiphar for the hypertension treatment Calvan Tablets (bevantolol). Nippon…
To read the full story
Related Article
BUSINESS
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Rakuten to Launch Japan PI of RM-0256 Photoimmunotherapy in April-June
February 17, 2026
- Kidswell, Treehill to Form US Firm for Cell Therapy Development
February 17, 2026
- Ono’s Velexbru Accepted for FDA Review in PCNSL
February 17, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





